SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at American Society of Clinical Oncology Annual Meeting

Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021

Surface Oncology to Present Clinical Updates for SRF388 and SRF617

Surface Oncology Expands Leadership Team with Key Executive Appointment and Promotions

Surface Oncology Named a 2021 Best Places to Work Company by Boston Business Journal

Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting

Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020